Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

Leverage these to understand future stock performance and identify high performing investment ideas. You can also filter these to get relevant data aligned with your investing style and specific ...

ASML’s competitive advantage and strong financials make it a buy. Learn why ASML stock’s reliance on top customers and AI ...